Content about Pharmaceutical Research and Manufacturers of America

WASHINGTON The Food and Drug Administration should ensure patient access, safety and efficacy; create a transparent and scientific regulatory structure; and enable innovation and competition when creating regulations governing follow-on biologics, according to testimony released in advance of an FDA hearing by a drug lobbying group.

WASHINGTON The companies working on more than half of the mental illness drugs under development are clustered in four U.S. states, according to research by the largest lobby for the drug industry.

The Pharmaceutical Research and Manufacturers of America compiled a study showing that of the 313 drugs, 192 are under development by companies in New York, New Jersey, North Carolina and California. The drugs are in clinical trials or under review by the Food and Drug Administration, PhRMA said.

WHAT IT MEANS AND WHY IT'S IMPORTANT It’s been said many times that the people you know are as important as what you know. In the case of Billy Tauzin, former president and CEO of the Pharmaceutical Research and Manufacturers of America, this adage was especially true, considering his former career as a member of Congress.

(THE NEWS: PhRMA names new president, CEO. For the full story, click here)